Drug Trial Radar · NCT00301392
Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT)
Last checked: Nov 19, 2026Latest source record: Sep 6, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,240
Actual
Start
Apr 2006
Primary completion
Mar 2012
Study completion Jun 2012
Sponsor
- Lead sponsor
- Tokyo UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 10, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 30 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effects of pitavastatin for preventing diabetes in a population with impaired glucose tolerance.
Conditions
- Diabetes Mellitus
- Glucose Intolerance
Interventions
life-style interventionOther
As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
Life style interventions plus concomitant use of pitavastatin.Drug
Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative incidence of diabetes based on 1 positive OGTT or fasting glucose levelsTime frame: from April, 2006 to end of March, 2012
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Tokyo, Graduate School of Medicine
Bunkyo-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.